b'Flow AML MRD Assay by MFC CytometryClinical Information Using a comprehensive selection of antibodies and Measurable residual disease, also called minimal residuala standardized panel across all testing points, MRD disease (MRD) refers to persistent leukemic cells in the bloodpopulations can be characterized and tracked down to 0.01% or bone marrow of cancer patients during or after treatment.sensitivity. Utilizing up to 12 biomarkers per tube allows for the identification of more LAIPS with less sample than previously Undetected or untreated MRD is a main cause was available before.Test Nameof cancer recurrence hence sensitive MRD tests are necessary for guiding optimal treatment programs andThis panel not only provides evaluation and monitoring AML MRD Assay by MFCIndications for Testingproviding a prognostic indicator for risk stratification of patients with hematological malignancy but provides of treated patients. a wide array of applications due to its comprehensiveAssay Type Identify tumor-specific markers forMulti-parameter Flow Cytometry (MFC) is a widely acceptedbiomarker selection. Multiparametric Flow Cytometry (12-color)post-treatment monitoringplatform for assessing MRD in patients with Acute MyeloidMonitor response to therapyLeukemia (AML) and can be performed within a short periodBiomarkers in AML MRD Panel CAP/CLIA-validated Monitor and evaluate for disease relapseof time. In our lab we utilize a comprehensive panel ofCD2, CD4, CD5, CD7, CD11b, CD13, CD14, CD15, CD16, CD19,and recurrenceantibody markers to characterize potential AML blast cells using a LAIP based different from normal (DfN) approach.CD33, CD34, CD36, CD38, CD45, CD 56, CD64, CD117, CD123,Method DescriptionThis approach takes into account information from diagnosis,HLADR, 7AAD 12 color Multiparametric Flow Cytometry with a sensitivity if available but also identifies aberrant cells that haveof 1x10 -4 .differentiated from normal maturation without previous patient history.Interpretation TurnaroundSpecimenShippingSpecimen Time Requirements Conditions StabilityAn interpretive24-48 hours3-5 mL of bone marrow inAmbient or Cool; Specimensreport will indicateEDTA or Sodium Heparin Do not freezeshould be stored References the presence/ at 2-8C and absence of AMLmust be received 1.Schuurhuis, Gerrit J et al. Minimal/measurable residual disease in AML: a consensus document from the Europeancell populations,by the lab within LeukemiaNet MRD Working Party. Blood vol. 131,12 (2018): 1275-1291. doi:10.1182/blood-2017-09-801498NCCNlevel of detection48 hours after 2.Wood BL. Acute Myeloid Leukemia Minimal Residual Disease Detection: The Difference from Normal Approach.Curr Protocin relation to thedrawCytom. 2020 Jun;93(1):e73. doi: 10.1002/cpcy.73.PMID: 32311834 clinical cutoff, 3.Cloos J, Harris JR, Janssen JJWM, Kelder A, Huang F, Sijm G, Vonk M, Snel AN, Scheick JR, Scholten WJ, Carbaat-Ham J,percent and Veldhuizen D, Hanekamp D, Oussoren-Brockhoff YJM, Kaspers GJL, Schuurhuis GJ, Sasser AK, Ossenkoppele G. Comprehensivenumber of aberrant Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acutemyeloblasts and Myeloid Leukemia. J Vis Exp. 2018 Mar 5;(133):56386. doi: 10.3791/56386.PMID: 29553571their associated 4.Short NJ, Ravandi F. How close are we to incorporating measurable residual disease into clinical practice for acute myeloidimmunophenotypic leukemia? Haematologica. 2019 Aug;104(8):1532-1541. doi: 10.3324/haematol.2018.208454. Epub 2019 Jul 4. PMID: 31273094;profile.PMCID: PMC6669140.5.Zeijlemaker W, Kelder A, Cloos J, Schuurhuis GJ. Immunophenotypic Detection of Measurable Residual (Stem Cell) Disease Using LAIP Approach in Acute Myeloid Leukemia.Curr Protoc Cytom. 2019 Dec;91(1):e66. doi: 10.1002/cpcy.66.PMID: 31763792 .6.Dix, C.; Lo, T.-H.; Clark, G.; Abadir, E. Measurable Residual Disease in Acute Myeloid Leukemia Using Flow Cytometry: A Review of Where We Are and Where We Are Going. J. Clin. Med. 2020, 9, 171460 LabPMM Services Catalog 2021|61'